Lactobacillus brevis LN-Ls1 with weight loss and lipid-lowering effects and application thereof
The product prepared using Lactobacillus sakei LN-Ls1 solves the problem of weight loss and lipid reduction in existing obesity treatments, achieving significant improvement in weight and blood lipids, and has good safety and application prospects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANDONG NEW TIME PHARMA CO LTD
- Filing Date
- 2026-03-26
- Publication Date
- 2026-06-23
AI Technical Summary
Existing obesity treatments are difficult to be effective in the long term for weight loss and lipid reduction, and there are also issues with safety and compliance. The effects of current probiotic products are limited.
Lactobacillus sakei LN-Ls1, as a live bacterium or its metabolites, is used to prepare lyophilized powders, granules, capsules, tablets, oral liquids, or beverages for weight loss and lowering blood lipids.
It significantly reduces weight and improves lipid metabolism without affecting food intake, with good safety and efficacy, and is superior to existing products.
Smart Images
Figure CN122256186A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of probiotics technology, specifically to a Lactobacillus sakei LN-Ls1 strain with weight loss and lipid-lowering effects and its applications. Background Technology
[0002] Obesity is a disease state caused by long-term excessive energy intake leading to fat deposition, resulting in damage to the body's physiology, function, and structure. Obesity is generally considered to be characterized by overweight, gut microbiota dysbiosis, insulin resistance, chronic inflammation, abnormal distribution and accumulation of white adipose tissue, and fibrosis.
[0003] Obesity can lead to the development of various chronic non-infectious diseases, such as type 2 diabetes, cardiovascular and cerebrovascular diseases, cancer, asthma, and chronic obstructive pulmonary disease, seriously endangering public health. Currently, diet control, exercise, surgery, and drug treatment are the main means of preventing and treating obesity. However, factors such as the difficulty in maintaining diet control and exercise for long periods, concerns about the risks of surgery, and the serious side effects of chemically synthesized drugs result in low willingness and adherence to medical treatment among obese patients.
[0004] In 2001, the Food and Agriculture Organization of the United Nations defined probiotics as live bacteria that, when ingested in appropriate amounts, have a beneficial effect on the health of the consumer. In recent years, research on probiotics has found that probiotics and their products have many beneficial effects on the human body, such as regulating gastrointestinal health, inhibiting pathogenic microorganisms, enhancing immune response, and lowering serum cholesterol.
[0005] The search for safer, more effective, and significantly fat-reducing methods is of paramount importance to human health. Summary of the Invention
[0006] In view of the above-mentioned prior art, the present invention provides a Lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects and its application.
[0007] To achieve the above objectives, the present invention adopts the following technical solution:
[0008] One aspect of the present invention provides a sake lactobacillus ( Lactobacillus sakei LN-Ls1, the Lactobacillus sakei with the effect of weight loss and lipid reduction, has the accession number CGMCC 30611.
[0009] One aspect of the present invention provides a microbial agent, characterized in that the microbial agent comprises Lactobacillus sakei LN-Ls1, which has the effect of weight loss and lipid reduction as described in claim 1.
[0010] The present invention also provides the application of Lactobacillus sakei LN-Ls1 or the bacterial agent described above, which has the effect of weight loss and lipid reduction, in the preparation of products with weight loss effect.
[0011] The present invention also provides the application of Lactobacillus sakei LN-Ls1 or the bacterial agent described above, which has the effects of weight loss and lipid reduction, in the preparation of products with the effect of lowering blood lipids.
[0012] Furthermore, the Lactobacillus sakei LN-Ls1 or the bacterial agent described therein, which has the effect of weight loss and lipid reduction, can reduce weight and improve lipid metabolism.
[0013] Furthermore, the product is a drug, health food, or ordinary food.
[0014] Furthermore, the Lactobacillus sakei LN-Ls1, which has weight-loss and lipid-lowering effects, is used in live form, with an effective daily dose of 1×10⁻⁶. 8 Up to 1×10 12 CFU.
[0015] Furthermore, the characteristic feature is that the Lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects is used in the form of inactivated bacteria or its metabolite postbiotic.
[0016] Furthermore, the product includes Lactobacillus sakei LN-Ls1, which has weight loss and lipid-lowering effects, and a pharmaceutically or food-grade acceptable carrier.
[0017] Furthermore, the dosage form of the product is lyophilized powder, granules, capsules, tablets, oral liquid, or beverage.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] The Lactobacillus sakei LN-Ls1 of this invention significantly reduces weight, improves blood lipid levels, and improves lipid metabolism without affecting food intake, thus exhibiting remarkable weight loss and lipid-lowering effects. Compared with existing products, it achieves superior technical results and has good safety and application prospects.
[0020] The preservation information of Lactobacillus sakei LN-Ls1, which has the effects of weight loss and lipid reduction, is as follows: Accession number: CGMCC 30611 Classification and nomenclature: Lactobacillus sakei Lactobacillus sakei Preservation Institution: China General Microbiological Culture Collection Center, China Microbiological Culture Collection Committee Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing Date of preservation: May 13, 2024. Attached Figure Description
[0021] To more clearly illustrate the technical solutions in this invention or the prior art, the accompanying drawings used in the specific embodiments will be briefly described below.
[0022] Figure 1 Effects on TC levels in obese mice, compared with NC, & P < 0.05 && P < 0.01; compared with MC, * P < 0.05 ** P < 0.01; compared with LN-Ls1, # P < 0.05.
[0023] Figure 2 Effects on TG levels in obese mice, compared with NC, & P < 0.05 && P < 0.01; compared with MC, * P < 0.05 ** P < 0.01; compared with LN-Ls1, # P < 0.05 ## P < 0.01.
[0024] Figure 3 Effects on LDL-C levels in obese mice, where compared with NC, & P < 0.05 && P < 0.01; compared with MC, * P < 0.05 ** P < 0.01; compared with LN-Ls1, # P < 0.05 ## P < 0.01.
[0025] Figure 4 Effects on HDL-C levels in obese mice, compared with NC, & P < 0.05 && P < 0.01; compared with MC, * P < 0.05 ** P < 0.01; compared with LN-Ls1, # P < 0.05 ## P < 0.01. Detailed Implementation
[0026] The technical solution of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0027] Unless otherwise specified, the experimental methods described in the following examples are conventional methods; unless otherwise specified, the reagents and materials are commercially available.
[0028] Group 1 Examples: Lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects of the present invention
[0029] This set of embodiments provides a *Lactobacillus sakei* strain with effects of relieving ulcerative colitis and broad-spectrum antibacterial activity. Lactobacillus sakei LN-Ls1, with accession number CGMCC NO. 30611.
[0030] Any act of culturing, propagating, fermenting, enriching, producing, preparing, using, inoculating, amplifying, transforming, modifying, altering, selling, or offering for sale a strain of Lactobacillus sakei LN-Ls1 with the accession number CGMCC NO. 30611 that has the effect of weight loss and lipid reduction falls within the protection scope of this invention.
[0031] Those skilled in the art can, based on actual production needs and in conjunction with conventional technical means or basic common sense in pharmaceutical production processes (e.g., "Encyclopedia of Pharmaceutical Technology", "Encyclopedia of Food and Food Production", "Lactic Acid Bacteria and Their Fermented Foods", "Research and Application of Microbial Agent Technology", etc.), routinely select or adjust pharmaceutical excipients, and then produce products with different dosage forms, storage conditions, and shelf lives from a strain of Lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects, which has the preservation number CGMCC NO. 30611. This is not a technical obstacle for those skilled in the art and is feasible and easy to do.
[0032] Group 2 Examples: Uses of Lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects according to the present invention
[0033] This set of embodiments provides Lactobacillus sakei LN-Ls1 with weight loss and lipid-lowering effects, with accession number CGMCC NO. 30611, for use in the preparation of weight loss, lipid-lowering products or for non-therapeutic purposes.
[0034] Experimental Example 1: Isolation of Lactobacillus sakei (LN-Ls1)
[0035] Measure 1 mL of Guangxi Deshengqing Baijiu and perform serial dilutions of the sample using sterile physiological saline. Select samples with appropriate dilution gradients and pour them into MRS agar medium containing bromocresol purple. Incubate at 37±1℃ for 36-48 h until single colonies grow. Select single colonies with different colors, sizes, and morphologies from the yellow acid-producing area of the plate and inoculate them into liquid MRS medium and incubate for 18-24 h. Streak inoculate them into MRS agar medium containing bromocresol purple for secondary screening. After three separation and purification processes, Gram staining is performed and morphological observation is performed under a microscope. Select strains with lactic acid bacteria morphology and preserve them in glycerol tubes.
[0036] Identification of Lactobacillus sakei (LN-Ls1)
[0037] Using the genomic DNA of *Lactobacillus sakei* (LN-Ls1) as a template for PCR amplification, PCR amplification was performed using universal 16S rDNA primers. After electrophoresis detection of the amplification products, they were sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing. The results showed that the 16S rDNA gene sequence of *Lactobacillus sakei* (LN-Ls1) of this invention is shown in SEQ ID NO.1:
[0038] The identified gene sequence was submitted to the NCBI database (www.ncbi.nlm.nih.gov) for BLAST analysis and comparison. Based on the molecular biological identification results, the strain was identified as *Lactobacillus sakei* and named *Lactobacillus sakei* LN-Ls1. The strain was deposited for preservation, and its preservation information is as follows: Accession number: CGMCC 30611 Classification and nomenclature: Lactobacillus sakei Lactobacillus sakei Preservation Institution: China General Microbiological Culture Collection Center, China Microbiological Culture Collection Committee Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing Date of preservation: May 13, 2024.
[0039] The commercially available strains (Lactobacillus sakei LSa 20 and Lactobacillus sakei Probio 65) used in the following experiments were purchased.
[0040] The effects of Lactobacillus sakei LN-Ls1 on body weight and lipid metabolism in obese mice.
[0041] Laboratory animals and grouping
[0042] Forty SPF-grade male C57BL / 6J mice, weighing 18-22g, were randomly divided into five groups according to body weight: normal group (NC), model group (MC), Lactobacillus sakei LN-Ls1 group (LN-Ls1), Lactobacillus sakei LSa20 group (LSa20), and Lactobacillus sakei Probio 65 group (Probio 65), with eight mice in each group.
[0043] Animal feed formulations are based on the AIN-76 formula, and the specific components are shown in Table 1.
[0044] Table 1. Composition of experimental diets for each group of animals
[0045] The normal control group (NC) was fed a standard maintenance diet, while the other mice were fed a high-fat diet. The model was considered successfully established when the body weight of the remaining mice (excluding the normal control group) exceeded that of the normal control group by 20%. Simultaneously, each treatment group was administered the corresponding test substance by gavage.
[0046] The normal group was fed a basal diet and administered physiological saline by gavage.
[0047] The model group MC was fed a high-fat diet and administered physiological saline by gavage.
[0048] Lactobacillus sakei LN-Ls1 group (LN-Ls1) was fed a high-fat diet and then administered 1g of the Lactobacillus sakei LN-Ls1 bacterial powder of the present invention by gavage, with a viable count of 1×10⁻⁶. 10 CFU / g;
[0049] Lactobacillus sakei LSa20 group (LSa20) was fed a high-fat diet and administered 1g of Lactobacillus sakei LSa20 powder by gavage, with a live bacteria count of 1×10⁻⁶. 10 CFU / g;
[0050] Lactobacillus sakei Probio 65 group (Probio 65) was fed a high-fat diet and administered 1g of Lactobacillus sakei Probio 65 bacterial powder by gavage, with a live bacteria count of 1×10⁻⁶. 10 CFU / g.
[0051] Each group was administered the medication once daily via gavage for 8 consecutive weeks. During the experiment, the mice in each group were observed daily for coat color, food intake, activity level, and mental state.
[0052] At room temperature (23±2)℃, with a 12:12h light-dark cycle, after the last feeding, the animal was fasted but allowed to drink water for 10 hours. Blood was drawn from the eyeballs, resulting in death. The liver, kidneys, heart, perirenal adipose tissue, and upper testis adipose tissue were carefully dissected, weighed, flash-frozen in liquid nitrogen, and stored at -80℃ for later use.
[0053] Determination of serum biochemical indicators
[0054] The centrifuged and stored serum was tested for TC, TG, HDL-C, and LDL-C levels according to the kit instructions.
[0055] Statistical analysis and graphing were performed using GraphPad Prism 8.0. The data are expressed as mean ± standard deviation. (±s) indicates that one-way ANOVA was used for comparisons among multiple groups. P <0.05 is considered statistically significant.
[0056] Results and Discussion
[0057] Effects on food intake in obese mice
[0058] There was no significant difference in food intake between the model group and each intervention group, indicating that the intervention groups had no effect on the food intake of the mice. The results are shown in Table 2.
[0059] Table 2 Effects on food intake in obese mice
[0060] Effects on body weight and body fat mass in obese mice
[0061] After 8 weeks of high-fat diet feeding, compared with the normal group, the body weight and visceral adipose tissue weight of mice in the model group increased significantly, and the obesity model was successfully established. Compared with the model group, the body weight, inguinal fat, and epididymal fat index of mice in each intervention group were significantly reduced.
[0062] Lactobacillus sakei LN-Ls1 was more effective than Lactobacillus sakei LSa20 and Lactobacillus sakei Probio 65 in reducing body weight, groin fat, and epididymal fat index. The results are shown in Table 3.
[0063] Table 3 Effects on food intake in obese mice
[0064] Note: Compared with NC, & P < 0.05 && P < 0.01; compared with MC, * P < 0.05 ** P < 0.01; compared with LN-Ls1, # P < 0.05 ## P < 0.01.
[0065] Effects on lipid metabolism parameters in obese mice
[0066] Compared with the normal group, the model group mice showed significantly increased levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), and significantly decreased levels of high-density lipoprotein cholesterol (HDL-C).
[0067] Compared with the model group, the levels of TC, TG and LDL-C in mice in the Lactobacillus sakei LN-Ls1 group were significantly reduced, while the level of HDL-C was significantly increased.
[0068] Compared with Lactobacillus sakei LSa20 and Lactobacillus sakei Probio 65, the LN-Ls1 group showed better effects in reducing TC, TG, and LDL-C levels, and better effects in increasing HDL-C levels. Results are shown below. Figure 1 , Figure 2 , Figure 3 , Figure 4 .
[0069] The Lactobacillus sakei LN-Ls1 of this invention significantly reduces weight, improves blood lipid levels, and improves lipid metabolism without affecting food intake, thus exhibiting significant weight loss and lipid-lowering effects. Compared with existing products, it achieves superior technical results.
[0070] The above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description, and any obvious variations or modifications derived therefrom are still within the scope of protection of this invention.
Claims
1. A type of sake lactobacillus ( Lactobacillus sakei LN-Ls1, characterized in that, The preservation number of the Lactobacillus sakei LN-Ls1 is CGMCC 30611.
2. The Lactobacillus sakei LN-Ls1 according to claim 1, characterized in that, The 16S rDNA sequence of the Lactobacillus sakei LN-Ls1 is shown in SEQ ID NO.
1.
3. The Lactobacillus sakei LN-Ls1 according to claim 1, characterized in that, The 16S rDNA sequence of the Lactobacillus sakei LN-Ls1 has at least 99%, 99.5%, 99.8%, 99.9%, or 100% identity with the sequence shown in SEQ ID NO.
1.
4. A microbial agent, characterized in that, The microbial agent comprises Lactobacillus sakei LN-Ls1 as described in claim 1.
5. The use of Lactobacillus sakei LN-Ls1 as described in claim 1 or the bacterial agent as described in claim 4 in the preparation of products with weight loss or lipid-lowering effects.
6. The application according to claim 5, characterized in that, The Lactobacillus sakei LN-Ls1 or the bacterial agent according to claim 4 can reduce body weight and improve lipid metabolism.
7. The application according to claim 5, characterized in that, The product is a drug, health food, or ordinary food.
8. The application according to claim 5, characterized in that, The Lactobacillus sakei LN-Ls1 is used in live form, with an effective daily dose of 1×10⁻⁶. 8 Up to 1×10 12 CFU.
9. The application according to claim 5, characterized in that, The Lactobacillus sakei LN-Ls1 is used in the form of an inactivated bacterium or its metabolite postbiotic.
10. The application according to claim 5, characterized in that, The product includes Lactobacillus sakei LN-Ls1 and a pharmaceutically or food-acceptable carrier; the dosage form of the product is lyophilized powder, granules, capsules, tablets, oral liquid or beverage.